title: A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
abstract: BACKGROUND
  The objective of this study was to evaluate safety and efficacy of Privigen®, a 10% intravenous immunoglobulin (IVIG), in a particular group of paediatric patients (highly sensitive to previous IVIG infusion) affected with Primary Immunodeficiencies (PID).
  
  
  METHODS
  Patients (n=8) from 3 to 17 years old diagnosed of PID who often suffered from adverse events related to the infusion to previous IVIG were switched to Privigen® in an open protocol. Data were prospectively collected regarding Privigen® administration: infusion, safety and efficacy. In parallel, data on safety and tolerance were retrospectively collected from medical charts regarding the previous 10% IVIG product used.
  
  
  RESULTS
  50% of the patients required premedication with previous IVIG. At the end of the study none required premedication with Privigen®. The infusion rate was lower than that recommended by the manufacturer. All patients had suffered through adverse events during previous IVIG infusion being severe in three patients and recurrent in the rest. With Privigen® only three patients suffered from an adverse event (all cases were milder than previous related). Trough levels of IgG remained stable. None suffer from any episode of bacterial infection.
  
  
  CONCLUSIONS
  The present work shows that Privigen® was safe in a group of hypersensitive paediatric patients who did not tolerate the administration of a previous 10% liquid IVIG by using a particular infusion protocol slower than recommended. The number of adverse effects was smaller than published, and all cases were mild. No premedication was needed. Privigen® was also effective in this small group.
authors.affiliation: Pediatric Allergy and Clinical Immunology Department of Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Lozano-Blasco
authors.affiliation: Pediatric Allergy and Clinical Immunology Department of Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain. Electronic address: martinmateos@hsjdbcn.org.
authors.forename: M A
authors.initials: MA
authors.lastname: Martín-Mateos
authors.affiliation: Pediatric Allergy and Clinical Immunology Department of Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Alsina
authors.affiliation: Pediatric Allergy and Clinical Immunology Department of Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain.
authors.forename: O
authors.initials: O
authors.lastname: Domínguez
authors.affiliation: Pediatric Allergy and Clinical Immunology Department of Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain.
authors.forename: M T
authors.initials: MT
authors.lastname: Giner
authors.affiliation: Pediatric Allergy and Clinical Immunology Department of Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Piquer
authors.affiliation: Pediatric Allergy and Clinical Immunology Department of Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Alvaro
authors.affiliation: Pediatric Allergy and Clinical Immunology Department of Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain.
authors.forename: A M
authors.initials: AM
authors.lastname: Plaza
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D008297:Male
chemical_list: D016756:Immunoglobulins, Intravenous